drug_type
RELEVANT_DRUG
intervention_type
Biologic (bispecific T-cell engager antibody)
drug_description
Bispecific T-cell–engager antibody immunotherapy that bridges CD19+ B cells and T cells, binding CD19 on B cells and engaging T cells to activate a cytotoxic response against CD19-expressing cells; administered IV once weekly; evaluated as monotherapy in relapsed/refractory CD19+ B-ALL.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Injections
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific antibody that links CD19+ B-lineage leukemia cells to T cells—binding CD19 on tumor cells and engaging T cells (via CD3) to trigger T-cell activation and cytotoxic killing of CD19-expressing cells.
drug_name
YK012
nct_id_drug_ref
NCT06580301